Evoke Pharma Reaffirms Commitment to Gastroparesis Patients
Evoke Pharma, Inc. (NASDAQ: EVOK), a pharmaceutical company focused on improving the lives of those affected by diabetic gastroparesis, has made it clear that its dedication remains strong in light of various changes in the medical field. Recently, the U.S. Food and Drug Administration (FDA) denied Vanda Pharmaceuticals' request for approval of its new drug candidate, Tradipitant, which aimed to alleviate symptoms of gastroparesis. This outcome has raised concerns among patients about the lack of effective treatment options for this multifaceted condition.
In reaction to this news, Evoke Pharma highlights the urgent need for more treatments tailored to manage gastroparesis, a condition where the stomach takes longer to empty, potentially causing severe gastrointestinal (GI) problems. Their flagship product, Gimoti (metoclopramide nasal spray), proudly holds the title of being the first and only FDA-approved nasal spray specifically aimed at treating acute and recurring diabetic gastroparesis in adults.
Focus on Patient Care
In a recent statement, Evoke Pharma's CEO, Matt D’Onofrio, spoke about the company's unwavering commitment to improving patient outcomes. He remarked, "Even though the regulatory landscape presents challenges, our focus on patient welfare is unchanged." Since its launch, Gimoti has been administered to over 4,000 patients, showcasing the company's proactive approach to educating healthcare providers and patients about the advantages of non-oral treatments.
Gimoti's Real-World Impact
Treating diabetic gastroparesis is complicated, especially as there is only one FDA-approved active ingredient—metoclopramide—available. Evoke emphasizes that conventional oral medications often fail due to poor absorption and nausea. In contrast, Gimoti's nasal delivery system offers more reliable symptom relief. This advantage was backed by substantial real-world data shared at relevant medical conferences.
During a study presented at Digestive Disease Week, findings revealed that patients using Gimoti had a 60% reduction in emergency room visits and a 68% drop in hospitalizations when compared to those taking oral metoclopramide over a six-month period. Notably, 61.5% of these patients had previously tried oral metoclopramide without finding symptom relief, highlighting Gimoti's potential to provide a new solution for these individuals.
Looking Ahead for Evoke
Evoke Pharma is dedicated to continuing its mission to create effective solutions for treating gastroparesis. With complications related to GLP-1 receptor agonists on the rise, the company is strategically positioning itself to provide healthcare professionals with the necessary data-driven insights for clinical decision-making. This ongoing progression will enable Evoke to meet the complex challenges of managing gastroparesis treatment.
Advocating for New Treatments
Chris Quesenberry, Evoke's Chief Commercial Officer, expressed the potential benefits of introducing new treatment options. He stated, "While we believe having additional therapies would enhance patient care, it's crucial for raising awareness and improving the diagnosis of a condition that has left many patients without a clear treatment plan for far too long." Navigating the process for new treatment approvals continues to be challenging, as seen by the fact that 14 treatments have failed to gain regulatory clearance over the last 15 years.
About Evoke Pharma, Inc.
Evoke Pharma is a specialized pharmaceutical company focused on creating treatments for gastrointestinal disorders, primarily through its innovative nasal spray, Gimoti. This product is designed to alleviate symptoms of diabetic gastroparesis, providing significant relief for patients dealing with this difficult condition. A standout feature of Gimoti is its ability to deliver medication effectively while avoiding complications often associated with oral options.
Diabetic gastroparesis affects patients around the globe, impairing the stomach's ability to process food properly. This delay can make it hard for individuals to absorb oral medications, further complicating their treatment plans. With Gimoti's approval, Evoke Pharma is offering a vital alternative to the oral and injectable treatments previously available, creating pathways for more effective patient management strategies.
Frequently Asked Questions
What is Evoke Pharma's primary focus?
Evoke Pharma mainly focuses on developing treatments for gastrointestinal disorders, especially diabetic gastroparesis.
What is Gimoti?
Gimoti is a nasal spray formulation of metoclopramide that has received FDA approval for treating acute and recurrent diabetic gastroparesis in adults.
How has Gimoti impacted patient care?
Gimoti has significantly improved patient outcomes, including decreases in emergency visits and hospitalizations, in comparison to oral medications.
Why is non-oral medication important for gastroparesis patients?
Non-oral medications provide effective solutions for patients who struggle with oral drug absorption and the management of their symptoms.
What challenges does Evoke Pharma face in the industry?
Evoke Pharma encounters difficulties in obtaining regulatory approval for new treatments, as shown by the high number of unsuccessful applications in recent years.
